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Abstract
Objectives
In October 2012, the Haitian Ministry of Health endorsed the “Option B+” strategy to elimi-
nate mother-to-child transmission of HIV and achieve HIV epidemic control. The objective of
this paper is to assess and identify risk factors for attrition from the national ART program
among Option B+ patients in the 12 months after ART initiation.
Design
This retrospective cohort study included patients newly initiating ART from October 2012-
August 2013 at 68 ART sites covering 45% of all newly enrolled ART patients in all regions
of Haiti.
Methods
With data from electronic medical records, we carried out descriptive analysis of sociodemo-
graphic, clinical, and pregnancy-related correlates of ART attrition, and used a modified
Poisson regression approach to estimate relative risks in a multivariable model.
Results
There were 2,166 Option B+ patients who initiated ART, of whom 1,023 were not retained
by 12 months (47.2%). One quarter (25.3%) dropped out within 3 months of ART initiation.
Protective factors included older age, more advanced HIV disease progression, and any
adherence counseling prior to ART initiation, while risk factors included starting ART late in
gestation, starting ART within 7 days of HIV testing, and using an atypical ART regimen.
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Discussion
Our study demonstrates early ART attrition among Option B+ patients and contributes evi-
dence on the characteristics of women who are most at risk of attrition in Haiti. Our findings
highlight the importance of targeted strategies to support retention among Option B+
patients.
Introduction
In October 2012, the Haitian Ministry of Health endorsed the “Option B+” strategy to acceler-
ate coverage of prevention of mother-to-child transmission of HIV (PMTCT) services toward
the dual goals of PMTCT and achieving overall HIV epidemic control by 2030 [1,2] Under this
strategy, pregnant and breastfeeding women living with HIV are routinely enrolled on lifelong
HIV antiretroviral therapy (ART) regardless of immunologic or clinical status, thereby
decreasing delays and barriers to ART enrollment [3,4]
HIV is among the top five causes of death and disability globally [5], and the high preva-
lence of HIV among adults of childbearing age results in approximately 240,000 perinatal HIV
infections annually[1]. Haiti accounts for the largest number of prevalent and incident HIV
infections in the Caribbean region [1], with prevalence among adult women of 2.7% [6]. In
2013, use of ARVs for PMTCT during childbirth was estimated at 87% among HIV-positive
women [7]. Despite this high coverage, it is estimated that 5.8–7.7% of pregnancies still result
in perinatal HIV infections, for a total of approximately 325–430 new pediatric HIV cases per
year [8,9] High retention on ART under Option B+ is critical to preserving the health of preg-
nant and postpartum women, achieving elimination of mother-to-child HIV transmission
(eMTCT), preventing transmission of HIV to sero-discordant partners, and preventing devel-
opment of antiretroviral drug resistance.
Early evidence from Option B+ programs globally shows rapid expansion in PMTCT cover-
age [3,10,11,12,13] but with a concerning pattern of elevated attrition among those newly
enrolling on ART [10,14] A retrospective cohort studies in Haiti by our research team, the par-
ent study to the present analysis, also demonstrated this pattern[15]. Among 17,059 newly initi-
ating ART patients, which adjusted for individual-level demographic and health characteristics,
we found up to a 59% greater risk of attrition among women enrolled on ART under Option
B+ compared to non-pregnant women. In the present study, we report on ART attrition out-
comes after ART start following adoption of the Option B+ policy in Haiti, using the subset of
the cohort with sufficient follow up time to observe 12 month outcomes. The aims of the pres-
ent study are: 1) to describe ART attrition among Option B+ patients in Haiti; and 2) to exam-
ine risk factors for ART attrition among Option B+ patients, with a specific focus on the timing
of HIV diagnosis, enrollment in care, and ART initiation relative to pregnancy. We also com-
pare outcomes in Haiti with outcomes reported from other settings. The study provides an
important contribution in the context of building a public health agenda, towards eMTCT and
“test and treat” goals [16,17]
Methods
Data source
The study used longitudinal electronic medical record (EMR) data from the iSante´ data sys-
tem, a networked system used in more than 100 health facilities where HIV care and treatment
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services are provided. The iSante´ system has been described elsewhere [18,19]. Facility-level
iSante´ data are securely replicated to a consolidated server housed within the Haitian Ministry
of Health (MSPP) in Port-au-Prince on a daily basis, or as Internet connectivity permits, and
the study used de-identified data from this iSante´ consolidated server. Records from health
facilities with out-of-date data, defined as having less than 90% of patient visit forms saved to
the iSante´ consolidated server within 90 days of the patient’s visit, were excluded from the
analysis. Each site had a study close date based on last replication of data to the consolidated
server on or before November 24, 2014. The study cohort was drawn from 68 out of 131
national ART sites, located in 9 out of 10 administrative Departments in Haiti, and covered
approximately 45% of all newly-enrolled ART patients in Haiti.
Study setting and population
Haiti’s PMTCT program has steadily evolved since the early 2000s. Starting in March 2009, for
women not already enrolled on ART for their own health, the PMTCT program adopted
Option B, with triple ART therapy after 28 weeks gestation through one week after cessation of
breastfeeding, regardless of CD4 count. Those who met the CD4-based ART eligibility thresh-
old of<350 cells/mm3 were advised to continue ART. Starting in June 2011, Option B was
recommended after 14 weeks gestation [20]. The adoption of Option B+ in 2012 reflected
MSPP’s consistent embrace of new strategies to reach national eMTCT goals. Over this period,
PMTCT services extended from 113 sites in 2008 to 137 sites in 2013 [8], and ART use in
PMTCT increased from 27% in 2008 to 87% in 2014 [7]. By 2014, 99% of the ARV regimens
used for PMTCT were multidrug regimens suitable for life-long therapy. Early infant diagnosis
services, first piloted in 2009 in Haiti, reached 3,600 HIV exposed infants in 2014, with a posi-
tivity rate of 5.3% [21].
In all of our study sites, PMTCT and ART services were located within the same health
facility. In general, Option B+ patients initiated ART through the maternal health service. The
national guidelines specify that transition of care to the ART service after cessation of breast-
feeding, although in some facilities transition occurred earlier. Most health facilities operate a
single ART pharmacy serving both PMTCT and other ART patients. The study used data on
patients newly enrolling on ART from October 2012, when the Option B+ policy was consid-
ered to be operationalized in Haiti, through August 2013. Patients with at least 365 days of fol-
low up time possible as of the health facility-specific study close date were included in the
analysis. The iSante´ system includes a de-duplication algorithm based on patient names and
demographic details; in the case of duplicates, the record with the first ART use was retained.
Patients with missing age or sex were excluded from the analysis (0.4% of records).
Measurements
The main outcome of interest was attrition from the ART program due to death or loss-to-fol-
low-up in the 12 months after ART initiation, under definitions used by the MSPP and the
President’s Emergency Plan for AIDS Relief (PEPFAR). The MSPP definition considers patients
to be cases of attrition if they made no visits for ART pick up within the 275–365 day period
after ART initiation. The PEPFAR definition considers patients to be cases of attrition if: 1)
after their last visit they did not have enough ARVs to last through the end of the 12th month of
treatment, or 2) if they died, stopped, or were lost to follow up. Both definitions count patients
who drop out of care for a time after ART initiation but who return to care by 12 months as
retained patients. We also considered the outcome of never returning to care after the ART
start visit and not returning to care in the first 90 days post-partum. This final outcome recog-
nizes that, among Option B+ patients, attrition as a function of time could be more closely
Haiti Option B+ ART attrition and risk factors
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related to timing of delivery than to timing since ART start. Known patient transfers to other
health facilities, representing either patients which were coded as transfers by health workers at
the index site or patients which were detected as transfers based upon the iSante´ de-duplication
algorithm, were excluded from the attrition analyses (n = 13,<1% patients).
The methodology for identifying Option B+ patients has been described elsewhere [15].
Briefly, the iSante´ data system contains information on pregnancy and labor and delivery, but
not on breastfeeding status, so patients who enrolled on ART during pregnancy or up to 12
weeks post-partum were considered as Option B+ patients. Among patients with evidence of
pregnancy but with no data on last menstrual period, gestational age, or an estimated or
observed delivery date, pregnancy dates were imputed, based upon the assumption that each
pregnancy-related visit fell at the mid-point of a typical pregnancy of 40-weeks duration. Very
few labor and delivery events are recorded within iSante´, reflecting the fact that only about
one-third of deliveries take place within a health facility in Haiti [6], as well as generally low
use of the iSante´ EMR within labor and delivery services.
Measurement of patient demographic and clinical covariates was consistent with our earlier
work [15]. Weight measures falling after the first trimester of pregnancy were not used to cal-
culate baseline body mass index (BMI), since pregnancy-related weight gain could distort a
patient’s BMI as a marker of nutritional status and health. We evaluated timing of HIV testing
relative to pregnancy, timing of enrollment in HIV care and treatment relative to pregnancy,
and gestational age at the time of ART initiation.
Data analysis
We used descriptive statistical analysis to characterize the patient population, by their demo-
graphic and clinical covariates. To compare the distribution of covariates across by attrition
status, we used the Chi-squared test of proportions for categorical covariates, and the Kruskal-
Wallis non-parametric test for numeric covariates. We examined the timing of last visit, and
analyzed interruptions in care among those who were retained at 12 months. We carried out
bivariate analyses to identify whether attrition levels varied by pregnancy-related covariates
(gestational age at ART initiation and timing of HIV testing relative to pregnancy). We limited
these analyses to patients with more precise pregnancy start and end dates available based
upon last menstrual period, gestational age, or estimated or observed delivery date. Unless oth-
erwise specified, we used the MSPP-defined attrition outcome in our analyses.
Finally, to explore factors associated with attrition among Option B+ patients, we carried out
adjusted analysis for the attrition outcome based upon the MSPP definition of retention. For all
bivariate and adjusted models, we used a modified Poisson regression approach to estimate rela-
tive risks (RRs). We used generalized estimating equations (GEE) models with a log link, a Pois-
son family, exchangeable correlation structure, and robust variance to address correlation of
data by health facility [22,23]. In the adjusted model approximately 10% of cases were complete
in all covariates. We used multiple imputation by chained equations to impute missing covariate
data for the GEE models. We specified 90 imputations, following the guideline that the number
of imputations be equal to the proportion of incomplete cases [24]. Multiple imputation is a rea-
sonable method when it is assumed that patterns in missingness can be explained by the
observed covariates. Stata 13.1 (Stata Corp, College Station, TX) was used for all analyses.
Ethical review
The study received scientific and ethical review and approval from the US Centers for Disease
Control and Prevention and the Haiti National Committee on Bioethics, and was exempted
from human subjects review by University of Washington.
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Results
There were 3,533 previously ART-naive Option B+ patients enrolled on ART from October
2012 through August 2014 in the cohort of the parent study. Of these, 2,166 women had at
least 12 months of time under study following ART initiation and were included in the present
analysis (Table 1). Only 968 patients (44.7%) had precise pregnancy start or end dates avail-
able, and only 850 patients (39.2%) had known dates for pregnancy and HIV testing. There
were also high levels of missing data in several covariates of interest, particularly household
size and presence of another known HIV+ person within the household, baseline body mass
index, WHO disease stage, and hemoglobin level.
Option B+ patients had a median age of 28.1 years, and were likely to be married or in a sta-
ble partnership (65.8%), live in the same commune as the health facility (67.9%), be asymp-
tomatic (43.4%), and be prescribed the first-line regimen of Tenofovir + Lamivudine +
Efavirenz (TDF-3TC-EFV) (80.9%) (Table 1). Many were started on Cotrimoxizole prophy-
laxis at ART start (66.5%), but few had ART adherence counseling documented (12.6%) or a
treatment supporter named at ART start (12.7%). Among those with known HIV testing dates,
the median time from HIV testing to ART start was 5 days (interquartile range or IQR: 0–12
days). Among those with known pregnancy and/or HIV testing dates, HIV testing typically
occurred at 15.5 weeks gestation (IQR: 7.0–23.9 weeks) while ART start typically occurred at
19.1 weeks gestation (IQR: 13.0–26.7 weeks) (Table 2). Only 18.2% of women registered for
HIV care before their pregnancy (Table 1).
At 12 months after ART start, 1,023 (47.2%) Option B+ patients experienced attrition
according to the MSPP definition, while 1,255 (57.9%) experienced attrition according to the
PEPFAR definition. Many women dropped out soon after their ART start, with 246 patients
(11.4%) never returning after their initial ART visit and 302 patients (13.9%) dropping out
within 3 months of ART initiation (Fig 1). Even among the 1,143 patients who were retained
on ART at 12 months (MSPP definition), a large proportion experienced at least one instance
of being 30 or more days late for an ART pick up visit during the first year on ART (59.1%)
(results not shown).
Those who started ART within 7 days of enrolling in HIV care (“rapid ART start”) were at
heightened risk for 12 month attrition (RR = 1.43; 95% confidence interval or CI: 1.24–1.64,
p<0.001) (results not shown). They were also at risk for early attrition; specifically, 15.3% of
patients with a rapid ART start never returned after their initial ART visit, while 5.3% of
patients with more time before starting ART never returned (RR = 2.70; 95% CI: 2.00–3.66,
p<0.001) (Fig 1). Timing of HIV testing relative to pregnancy and gestational age at ART start
were also important. Among the 850 women with known pregnancy and HIV testing dates,
the 687 women (80.8%) who first enrolled in HIV care after the start of pregnancy had a 2-fold
risk of attrition compared to those who were diagnosed with HIV before pregnancy (RR =
2.06, 95% CI: 1.60–2.65, p<0.001) (Fig 1). Among the 968 women with known pregnancy
dates, those who initiated ART in the last 10 weeks of pregnancy were at higher risk of ART
attrition, compared to those who initiated in the first 20 weeks of gestation (RR = 1.52, 95%
CI: 1.30–1.7; p<0.01) (Fig 2).
In the adjusted analyses, significant protective factors with respect to ART attrition were
older age (RR = 0.89, 95% CI: 0.86–0.93 for each 5-year increase in age, p<0.0001), having
more advanced HIV disease progression by clinical staging or baseline CD4 (RR = 0.88, 95%
CI: 0.77–1.00 for stage III/IV vs. I/II, p<0.05), and having any counseling on ART adherence
prior to ART initiation (RR = 0.74, 95% CI: 0.62–0.88, p<0.01) (Table 3). Significant risk fac-
tors were starting ART at 30–40 weeks gestation (RR = 1.20, 95% CI: 1.02–1.42, p = 0.03),
Haiti Option B+ ART attrition and risk factors
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Table 1. Characteristics of Option B+ patients (Categorical variables).
Option B+ Attritionǂ p-valueǁ
n % n %
Total 2,166 100.0% 1,023 47.2%
Marital status
Married/concubinage 1,425 65.8% 683 66.8% 0.67
Widow/divorce 90 4.2% 38 3.7%
Single 236 10.9% 107 10.5%
Missing/Unknown 415 19.2% 195 19.1%
Location of residence
Different commune 647 29.9% 303 29.6% 0.70
Same commune 1,470 67.9% 694 67.8%
Missing 49 2.3% 26 2.5%
HIV+ household member
No 818 37.8% 363 35.5% <0.001
Yes 106 4.9% 35 3.4%
Missing 1,242 57.3% 625 61.1%
Household size
1–3 members 698 32.2% 314 30.7% <0.001
>3 members 226 10.4% 84 8.2%
Missing 1,242 57.3% 625 61.1%
WHO stage
I 941 43.4% 468 45.7% <0.001
II 517 23.9% 231 22.6%
III 369 17.0% 145 14.2%
IV 100 4.6% 44 4.3%
Missing 239 11.0% 135 13.2%
Period of ART start
Oct12-Mar13 893 41.2% 401 39.2% 0.13
Apr13-Sep13 1,086 50.1% 536 52.4%
Oct13-Mar14 187 8.6% 86 8.4%
Starting ART regimen
AZT-3TC-EFV 201 9.3% 82 8.0% 0.11
AZT-3TC-NVP 155 7.2% 80 7.8%
TDF-3TC-EFV 1,752 80.9% 829 81.0%
All Other 58 2.7% 32 3.1%
Supportive services at ART start
Treatment supporter named 274 12.7% 102 10.0% <0.001
Counseling before ART start 273 12.6% 77 7.5% <0.001
Treatment or prophylaxis for opportunistic infections at ART start
TB prophylaxis or treatment 542 25.0% 269 26.3% 0.20
Cotrimoxizole prophylaxis 1,441 66.5% 646 63.1% <0.01
Pregnancy
Dates of pregnancy known* 968 44.7% 439 42.9% 0.12
Dates of HIV test and pregnancy known 850 39.2% 389 38.0% 0.27
HIV test after start of pregnancy** 687 80.8% 350 51.0% <0.001
(Continued )
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starting ART within 7 days of HIV testing (RR = 1.19, 95% CI: 1.05–1.34, p<0.01), or having
an atypical ART regimen prescribed (RR = 1.35, 95% CI: 1.08–1.69, p<0.01) (Table 3).
Discussion
In the context of Haiti’s eMTCT agenda and the MSPP’s adoption in June 2016 of the universal
“test and treat” approach to HIV care and treatment, our findings provide important evidence
about sub-optimal retention on ART among women who initiate ART during or after preg-
nancy under Option B+. Haiti’s national PMTCT program has made important gains in recent
years. Still, closing the “last mile” to achieve eMTCT will require improved retention on ART
during pregnancy and post-partum periods and beyond.
Table 1. (Continued)
Option B+ Attritionǂ p-valueǁ
n % n %
Registered for HIV care after preg start*** 792 81.8% 398 50.3% <0.001
ǂAttrition by MSPP definition.
ǁp-value for Chi-2 test statistic comparing attrition and non-attrition cases.
*Pregnancy dates were considered to be known when data were available on last menstrual period date, gestational age, estimated delivery date, or actual
delivery date.
**Among cases with dates of HIV test and pregnancy known.
***Among cases with dates of pregnancy known.
AZT = Zidovudine; 3TC = Lamivudine; NVP = Nevirapine; TDF = Tenofovir; EFV = Efavirenz.
doi:10.1371/journal.pone.0173123.t001
Table 2. Characteristics of Option B+ patients (Continuous variables).
Option B+ p-valueǁ
n % missing median IQR
Age at ART start (years) 2166 0% 28.1 (23.9, 33.1) <0.001
Body mass index 285 87% 22.5 (20.5, 25.9) 0.10
Hemoglobin 1055 51% 10.7 (9.8, 11.7) <0.01
Time: HIV test to registration (days) 1614 25% 0 (0, 1) 0.03
Time: registration to ART start (days) 2166 0% 1 (0, 62) <0.001
Time: HIV test to ART start (days) 1614 25% 5 (0, 120) <0.001
Gestational age at HIV test (weeks) 850 61% 15.5 (7.0, 23.9) <0.001
Gestational age at ART start (weeks) 968 55% 19.1 (13.0, 26.7) <0.001
Attritionǂ p-valueǁ
n % missing median IQR
Age at ART start (years) 1023 0% 27.0 (22.8, 31.9) <0.001
Body mass index 54 95% 21.6 (20.1, 24.2) 0.10
Hemoglobin 428 58% 10.6 (9.6, 11.6) <0.01
Time: HIV test to registration (days) 758 26% 0 (0, 1) 0.03
Time: registration to ART start (days) 1023 0% 0 (0, 18) <0.001
Time: HIV test to ART start (days) 758 26% 2 (0, 34) <0.001
Gestational age at HIV test (weeks) 389 62% 17.7 (11.0, 25.1) <0.001
Gestational age at ART start (weeks) 439 57% 21.0 (14.1, 28.7) <0.001
ǂ Attrition by MSPP definition
ǁ Kruskal—Wallis equality of populations rank test (with ties) comparing variable values between attrition and non-attrition cases.
doi:10.1371/journal.pone.0173123.t002
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Our study raises notable concerns about the high level of early ART attrition among Option
B+ patients throughout Haiti. It demonstrates the profile of women at highest risk of attrition
from the Option B+ program: younger women, women newly diagnosed with HIV during
pregnancy or post-partum, women who initiated ART soon after diagnosis, and women who
initiated ART late in pregnancy. Women who immediately move into the ART enrollment
process upon learning their HIV diagnosis face the challenge of accepting their diagnosis and
assimilating information about HIV treatment at the very time they are expected to start taking
ART medications. Those who tested days or weeks before ART initiation would have had a
Fig 1. Timing of last visit in 12 months after ART start. *Among 2,166 Option B+ clients. **Among 850 Option B+ clients with
known pregnancy and HIV testing dates. Rapid ART start = ART start within 7 days of registration in HIV care; No rapid ART
start = ART start >7 days after registration in HIV care. ǂp<0.001 for Chi2 test of equality of proportions between Rapid ART start
vs. No rapid ART start and between HIV test before vs. after start of pregnancy.
doi:10.1371/journal.pone.0173123.g001
Fig 2. ART attrition indicators by gestational age at ART start. **Among 968 Option B+ patients with available data on pregnancy
dates. ǂ p<0.001 ǁ p = 0.01 * p = 0.54 for Chi2 test of equality of proportions across gestational age groups.
doi:10.1371/journal.pone.0173123.g002
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greater chance to accept their diagnosis or disclose their HIV status to others, leading to lower
risk of attrition. Our finding that having ART adherence counseling prior to ART initiation
was protective suggests that a greater level of counseling and support at the time of enrollment
is helpful; however, this finding deserves cautious interpretation. It is possible that ART adher-
ence counseling was given in some sites, but without capturing data on this within the iSante´
data system. We were unable to distinguish between the service not being offered and the data
not being collected.
Our evidence on a national scale corroborates results from a study of ART retention out-
comes at a single Departmental hospital in Les Cayes in Southern Haiti, during the era of the
Option B approach from 2009–12 [20]. That study found elevated loss to follow up among
those with HIV diagnosis during vs. before pregnancy and with ART initiation during the
third trimester of pregnancy, although their results were not statistically significant in adjusted
analyses. A recent mixed methods study on the PMTCT care cascade, sponsored by the MSPP
and the Pan American Health Organization, investigated reasons women dropped out of
PMTCT programs. The study focused on 10 health facilities in the 4 Departments of Haiti
located along the border with the Dominican Republic, and was able to locate and interview
Table 3. Risk factors for ART attrition among Option B+ patients*.
Adjusted Relative Risk 95% Confidence Interval p-value
Marital status
Non-married vs. married 0.97 (0.83, 1.12) 0.67
Age
Each 5-year increase 0.89 (0.86, 0.93) <0.0001
Household characteristics
Live in same commune as health facility 0.94 (0.80, 1.10) 0.42
4+ members vs. 1–3 members 0.98 (0.82, 1.17) 0.81
Known HIV+ household member 0.80 (0.60, 1.06) 0.13
Timing of ART start
Gestational age 30–40 weeks at ART start 1.20 (1.02, 1.42) 0.03
ART start within 7 days of HIV test 1.19 (1.05, 1.34) <0.01
Period of ART initiation (reference = Oct12-Mar13)
Apr13-Sep13 1.06 (0.95, 1.19) 0.26
Oct13-Mar14 0.97 (0.81, 1.18) 0.79
ART starting regimen (reference = TDF+3TC+EFV)
AZT-3TC-NVP 1.06 (0.83, 1.36) 0.62
AZT-3TC-EFV 0.88 (0.72, 1.07) 0.21
All other 1.35 (1.08, 1.69) <0.01
Clinical status at ART start
WHO stage III/IV vs. I/II 0.88 (0.77, 1.00) <0.05
BMI (each 1 unit increase) 0.94 (0.94, 1.01) 0.23
Moderate or severe anemia 1.08 (0.91, 1.28) 0.35
Supportive services at ART start
Treatment buddy named 0.86 (0.70, 1.06) 0.15
Pre-ART counseling provided 0.74 (0.62, 0.88) <0.01
Treatment or prophylaxis for opportunistic infections at ART start
Tuberculosis-related therapy 1.03 (0.87, 1.22) 0.74
Cotrimoxazole therapy 0.94 (0.82, 1.07) 0.37
* Attrition by MSPP definition.
doi:10.1371/journal.pone.0173123.t003
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56/179 PMTCT patients (31%) who were lost to follow up from those facilities [25]. Key
themes explaining loss to follow up were: lack of money to cover transport to the clinic and
time away from economic activities, denial of HIV status (including a belief that a negative
PCR result for the infant indicated a negative status in the mother), stigma and lack of disclo-
sure to partners and family members, migration, ART side effects, and dissatisfaction with
clinic services based upon wait time, reception, and concerns that health workers would fail to
protect confidentiality.
Haiti’s experience with retention on ART following adoption of Option B+ echoes early
results from other countries, as described in both quantitative and qualitative studies. In
Malawi, at the start of the Option B+ program in 2011–12, 23.2% of Option B+ patients were
not retained on ART after 12 months [10,26], with wide variation in outcomes across facilities
[27]. In a rural area of Northern Mozambique, attrition at 12 months was reported among
64.9% of Option B+ patients [28]. Younger age [26,27,29] and rapid ART initiation following
HIV diagnosis [28,30] have each been demonstrated as risk factors for attrition under Option
B+ in other settings. Reasons for lost to follow up in Malawi based upon qualitative research
[31,32] appear similar to reasons reported in Haiti [20,25].
In the early days of Haiti’s ART program, when only the sickest patients met ART eligibility
criteria, a treatment buddy (or “accompagnateur”) model, involving directly observed therapy
by community health workers, was the main model used in Haiti to reinforce ART adherence
and retention in care [33]. As the ART program expanded nationally in Haiti, this model was
adapted to a volunteer-based model where patients could name a friend or family member as a
treatment buddy who could accompany the patient to clinic visits, collect medications on
behalf of the patient, and otherwise support them. This voluntary treatment buddy model has
its limitations in the context of ART use by patients who are not obviously sick, and retention
support models have evolved in Haiti over time in recognition of the multi-level challenges to
ART retention. Recently, the MSPP and its technical assistance partners have undertaken sev-
eral promising initiatives to increase ART retention, including moves toward multi-month
prescriptions and “rapid pathway” services for stable ART patients, community-based ART
distribution, and active tracing of patients within 1–2 weeks of missed visits [34]. Several strat-
egies for improving ART retention among pregnant women have shown promise in other
countries, including promotion of couples testing [35,36], clinic- or community-based peer
support [35,37,38,39], case management using community health workers [40], clinic level
systems analysis and workflow re-design and other quality improvement approaches
[35,41,42,43]. Targeted retention support initiatives for pregnant and post-partum women,
especially younger women, need to be systematically tested in Haiti to reveal which innova-
tions are most effective and cost-effective to optimize Option B+.
Strengths of our study were the large number of patients and facilities covered by the EMR
data source and the ability to investigate the relationship between timing of pregnancy, HIV
testing, enrollment in care, and ART start based upon patient-level EMR data. A limitation
was the lack of precise pregnancy start and end dates and HIV testing dates among many
patients, meaning our results on timing of ART start during pregnancy may not reflect the
broader population of Option B+ patients. Another limitation was that reasons for ART dis-
continuation at any given health facility were only documented in 26% of non-retained
patients, so transfers of care to other health facilities could have been under-reported. How-
ever, our previous analyses suggest that “silent transfer” explains <10% of cases of attrition
[15]. Our findings on rapidly starting ART as a risk factor for ART attrition may reflect selec-
tion bias in that those who return to initiate ART days or weeks after HIV diagnosis may be
inherently more likely to remain in care. Finally, while the study raises an interesting hypothe-
sis about the helpful role of ART adherence counseling prior to ART start among Option B+
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patients, this finding deserves cautious interpretation. Further investigation of the variation in
ART enrollment processes and quality of patient education and counseling at ART initiation
across health facilities under Option B+ would be helpful, and interventions to strengthen
ART adherence counseling at the time of ART initiation would need to be tested via an experi-
mental or quasi-experimental study design.
Conclusion
Our study reports on the retention outcomes of a large cohort of newly-enrolled ART patients
from 68 health facilities in Haiti following the adoption of the Option B+ policy in October
2012. Women of younger age, who tested for HIV after the start of pregnancy, who enrolled
on ART late in pregnancy, who had little time between HIV diagnosis and ART initiation, and
who had no pre-ART counseling were at particular risk of attrition. This highlights the impor-
tance of finding feasible strategies to support retention in care among these women, in order
to fulfill the eMTCT and “test and treat” agendas in Haiti.
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